Mirabegron – a selective 3-adrenoreceptor agonist for the treatment of overactive bladder

abegron – a selective 3-adrenoreceptor agonist for the treatment of overactive bladder Review (2008) Total Article Views Authors: Bhide AB, Digesu GA, Fernando R, Khullar V Published Date July 2012 Volume 2012:4 Pages 41 - 45 DOI: http://dx.doi.org/10.2147/RRU.S28930 Received: 01 May 2012 Accepted: 12 June 2012 Published: 16 July 2012 Alka A Bhide, G Alessandro Digesu, Ruwan Fernando, Vik Khullar Department of Urogynaecology, St Mary's Hospital, London, United Kingdom Abstract: Overactive bladder is a common condition that significantly impacts overall quality of life. Antimuscarinics are the current main pharmacological option for treatment; however, many patients fail to adhere to therapy due to troublesome side effects. Mirabegron is a new beta-3 adrenoreceptor agonist which causes detrusor smooth muscle relaxation and has been proposed to be effective for treating overactive bladder symptoms. Mirabegron has been shown to be superior to placebo for reducing the mean number of incontinence episodes per 24 hours and the mean number of micturitions per 24 hours. Side effects such as dry mouth were observed at similar or lower rates than those seen for placebo and antimuscarinics. Higher doses of mirabegron were associated with minor increases in pulse rate and mean blood pressure. Mirabegron offers a new alternative for treating overactive bladder in patients for which antimuscarinics are either not tolerated or not appropriate.